DIGP — Hypha Labs Share Price
Last trade - 00:00- $1.91m
- $1.92m
- 40
- 36
- 27
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 11.73 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.55 | 2.57 | 2.5 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hypha Labs, Inc., formerly Digipath, Inc., has developed technology that cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom's mycelium into a natural product. This product has an exact, consistent potency containing all the natural compounds found in these fungi. Typically, it takes six-eight weeks to fully grow mushrooms, and using its technology, the production of the active ingredient is only seven-10 days. This natural product solves the dosing issue created by having to use whole mushrooms. The product is tasteless and gentler on the stomach and can be used sublingually for fast-acting results. The product allows the consumer to produce measurable active ingredients at home for mental and physical benefits. It provides Psilocybin Mushrooms, Button Mushrooms, Shiitake Mushrooms, Maitake Mushrooms, Reishi Mushrooms, Lion's Mane Mushrooms, Oyster Mushrooms, Oyster Mushrooms and Crimini Mushrooms.
Directors
- Last Annual
- September 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 5th, 2010
- Public Since
- December 23rd, 2011
- No. of Employees
- 17
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 105,280,155
- Address
- 5940 S. Rainbow Boulevard, LAS VEGAS, 89118
- Web
- https://www.digipath.com/
- Phone
- +1 7027440640
- Auditors
- Fruci & Associates II, PLLC
Upcoming Events for DIGP
Similar to DIGP
Adia Nutrition
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
AiXin Life International
Pink Sheets on Nasdaq
FAQ
As of Today at 20:18 UTC, shares in Hypha Labs are trading at $0.02. This share price information is delayed by 15 minutes.
Shares in Hypha Labs last closed at $0.02 and the price had moved by +207.14% over the past 365 days. In terms of relative price strength the Hypha Labs share price has outperformed the S&P500 Index by +157.77% over the past year.
There is no consensus recommendation for this security.
Hypha Labs does not currently pay a dividend.
Hypha Labs does not currently pay a dividend.
Hypha Labs does not currently pay a dividend.
To buy shares in Hypha Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.02, shares in Hypha Labs had a market capitalisation of $2.26m.
Here are the trading details for Hypha Labs:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: DIGP
Based on an overall assessment of its quality, value and momentum Hypha Labs is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hypha Labs. Over the past six months, its share price has underperformed the S&P500 Index by -40.09%.
As of the last closing price of $0.02, shares in Hypha Labs were trading -6.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hypha Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hypha Labs' management team is headed by:
- A. Stone Douglass - CHM
- Todd Denkin - PRE
- Dennis Hartman - IND
- Bruce Raben - IND